ERBB2 and breast cancer: A similar trend was observed in CD8+ T cells treated with phenelzine ex vivo derived from a stage IV ER/PR+/HER2 metastatic breast cancer patient (Supplementary Figure 3C) and a progressive disease (PD) melanoma patient (Supplementary Figure 3D).